Moderna (MRNA) Share-based Compensation (2018 - 2026)
Moderna (MRNA) posted quarterly Share-based Compensation of $120.0 million for Q2 2026, down 7.69% year-over-year from $130.0 million in Q2 2025, and up 15.38% on a QoQ basis from $104.0 million in Q1 2026.
Moderna (MRNA) Share-based Compensation (2018 - 2026) Analysis & Trends
Moderna has reported Share-based Compensation for 9 years, with the latest figure at $120.0 million in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $120.0 million, down 7.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $462.0 million (changed 0.22% YoY), and the FY2025 annual result was $483.0 million, up 12.59% from the prior year.
- Share-based Compensation grew to $120.0 million in Q2 2026, from $104.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $130.0 million in Q2 2025 and troughed at $44.0 million in Q1 2022.
- A 5-year average of $92.6 million and a median of $102.5 million in 2024 frame the typical range for Share-based Compensation.
- The widest annual swing landed in 2022, when Share-based Compensation jumped 75.0%; it then retreated 9.57% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $62.0 million in 2022, then climbed by 27.42% to $79.0 million in 2023, then jumped by 31.65% to $104.0 million in 2024, then gained by 8.65% to $113.0 million in 2025, then increased by 6.19% to $120.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $120.0 million in Q2 2026, $104.0 million in Q1 2026, and $113.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 120.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.00 Mn |
| Jun 30, 2026 | 120.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 113.00 Mn |
| Dec 31, 2025 | 113.00 Mn |
| Sep 30, 2025 | 125.00 Mn |
| Sep 30, 2025 | 125.00 Mn |
| Jun 30, 2025 | 130.00 Mn |
| Jun 30, 2025 | 130.00 Mn |
| Mar 31, 2025 | 115.00 Mn |
| Mar 31, 2025 | 115.00 Mn |
| Dec 31, 2024 | 429.00 Mn |
| Dec 31, 2024 | 429.00 Mn |
| Dec 31, 2023 | 79.00 Mn |
| Dec 31, 2023 | 79.00 Mn |
| Sep 30, 2023 | 77.00 Mn |
| Sep 30, 2023 | 77.00 Mn |
| Jun 30, 2023 | 74.00 Mn |
| Jun 30, 2023 | 74.00 Mn |